PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 23, 2026Gynecologic Oncology1 citationsOpen Access

Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025)

AOAiko OgasawaraSSShiro SuzukiKOKatsutoshi Oda

Key Points

  • This study aims to evaluate the safety and clinical activity of pembrolizumab combined with olaparib in patients with recurrent cervical cancer after platinum-based chemotherapy.
  • Conducted a Phase II clinical trial
  • Administered pembrolizumab and olaparib to patients
  • Monitored safety and clinical activity
  • Combination therapy exhibited an acceptable safety profile
  • Limited additional clinical activity observed
  • Need for appropriate biomarkers identified for effective treatment

Abstract

Pembrolizumab and Olaparib combination therapy demonstrated an acceptable safety profile. Pembrolizumab plus olaparib showed manageable safety in platinum-experienced recurrent cervical cancer. Adding PARP inhibitor to PD-1 blockade demonstrated limited additional clinical activity in this setting. Appropriate biomarkers may be needed for pembrolizumab plus olaparib.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ogasawara et al. (2026) studied this question.

synapsesocial.com/papers/69e9b6aa85696592c86eb088https://doi.org/10.1016/j.ygyno.2026.04.007
Ask AI
Helpful
Bookmark
Share
View Full Paper